Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: BJU Int. 2015 Jul 4;118(1):68–76. doi: 10.1111/bju.13193

Fig. 1.

Fig. 1

Disposition of cohort in active surveillance: patients with favorable-risk prostate cancer (Gleason score ≤6 [3 + 3] with no more than 1 positive biopsy core [tumor, <3 mm] or Gleason score 7 [3 + 4] with no more than 1 positive biopsy core [tumor, <2 mm] and PSA level <4 ng/mL).